On June 12, 2021 PDX Pharmaceuticals, reported that in collaboration with the Knight Cancer Institute and the Biomedical Engineering Department of Oregon Health and Science University, co-authored a paper published in the Advanced Materials Journal, which describes our immuno-nanotherapeutic candidate, Augmenting Immune Response and Inhibiting Suppressive Environment of the tumors, AIRISE-02 (Press release, PDX Pharmaceuticals, JUN 12, 2021, View Source [SID1234584751]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AIRISETM is based on co-delivery of selected therapeutics (siRNA and adjuvant) to trigger anti-tumor immune response. AIRISE-02 is injected locally to the tumor, and uses that tumor as a depot of neo-antigens to train the body’s own immune system to attack cancer elsewhere in the body (e.g., untreated distant or metastatic tumors). The paper shows results in melanoma, breast, and colon tumor models.

62% cure rate (complete regression of both treated and untreated tumors; survival monitored up to 500 days) was achieved in an aggressive melanoma tumor model, when AIRISE-02 was combined with immune checkpoint inhibitors. On the other hand, in this same model, no cure was achieved with immune checkpoint inhibitors alone.